Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings

Zacks01-23

Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2024 results on Jan. 30, before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. Thermo Fisher’s...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505016409?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 20:32","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2505016409","market":"us","top_or_hot":-1,"title":"Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings","media":"Zacks","content":"<div>\n<p>Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2024 results on Jan. 30, before market open.\nSee the Zacks Earnings Calendar to stay ahead of market-making news. \nThermo Fisher’s...</p>\n\n<a href=\"https://finance.yahoo.com/news/robust-analytical-instruments-segment-likely-123200505.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRobust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-23 20:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/robust-analytical-instruments-segment-likely-123200505.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2024 results on Jan. 30, before market open.\nSee the Zacks Earnings Calendar to stay ahead of market-making news. \nThermo Fisher’s...</p>\n\n<a href=\"https://finance.yahoo.com/news/robust-analytical-instruments-segment-likely-123200505.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMO","symbol_name":"赛默飞世尔","start_time":0,"source_url":"https://finance.yahoo.com/news/robust-analytical-instruments-segment-likely-123200505.html","article_id":"2505016409","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505016409","pubTimestamp":1737635520,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2024 results on Jan. 30, before market open.See the Zacks Earnings Calendar to stay ahead of market-making news.Thermo Fisher’s third-quarter earnings of $5.28 per share beat the Zacks Consensus Estimate by 0.6%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.63%.The Zacks Consensus Estimate for revenues is pegged at $11.25 billion, suggesting 3.3% growth from the prior-year quarter’s reported figure. The consensus mark for earnings is pegged at $5.92 per share, indicating 4.4% growth from the year-ago quarter’s reported numbers.Meanwhile, the bioproduction business has likely grown in the quarter, banking on strong adoption in the pharma and biotech segment. Within this business, the company introduced Gibco CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8, which expanded on Thermo Fisher’s CTS Detachable Dynabeads platform.Meanwhile, TMO is expected","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMO":"赛默飞世尔"},"translate_title":"强劲的分析仪器部门可能有助于TMO第四季度盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMO":1},"content_text":"Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2024 results on Jan. 30, before market open.\nSee the Zacks Earnings Calendar to stay ahead of market-making news. \nThermo Fisher’s third-quarter earnings of $5.28 per share beat the Zacks Consensus Estimate by 0.6%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.63%.\nTMO’s Q4 Estimates\nThe Zacks Consensus Estimate for revenues is pegged at $11.25 billion, suggesting 3.3% growth from the prior-year quarter’s reported figure. The consensus mark for earnings is pegged at $5.92 per share, indicating 4.4% growth from the year-ago quarter’s reported numbers.\nEstimate Revision Trend Ahead of Earnings\nEstimates for Thermo Fisher’s fourth-quarter earnings have remained unchanged at $5.92 per share in the past 30 days.\nNow, let's look at how things might have progressed for the MedTech major prior to the announcement.\nFactors at Play\nThermo Fisher’s Analytical Instruments segment is expected to have generated strong fourth-quarter sales, banking on its newly launched cutting-edge technologies. The segment is expected to benefit from its electron microscopy business. In the fourth quarter, the company introduced the Thermo Scientific Iliad (Scanning) Transmission Electron Microscope, which integrates a number of TMO’s advanced analytical technologies into a seamless and user-friendly workflow. \nIn the third quarter, the R&D 100 Awards honored Thermo Scientific Orbitrap Astral Mass spectrometer in the market disruptors special recognition category. Additionally, per management, the adoption of Thermo Scientific’s Orbitrap Astral continues to be incredibly strong. We expect these developments to have contributed to TMO’s fourth-quarter revenues.\nPer our model, Thermo Fisher’s Analytical Instruments business should earn $2.19 billion in revenues, suggesting 7.5% growth year over year.\nWithin the Life-Science Solutions segment, the company is likely to have experienced a sales decline due to the runoff of pandemic-related revenues. In May 2023, WHO declared an end to COVID-19 as a public health emergency. \nWithin this segment, in the third quarter, the company launched the Applied Biosystems MagMAX Sequential DNA/RNA kit, which helps researchers identify unique insights into cancer-causing genetic alterations. Also, TMO introduced Invitrogen Vivofectamine Delivery Solutions, which delivers nucleic acids to multiple targets with therapeutic effects. These developments might have turned in favor of Thermo Fisher in the fourth quarter. \nMeanwhile, the bioproduction business has likely grown in the quarter, banking on strong adoption in the pharma and biotech segment. Within this business, the company introduced Gibco CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8, which expanded on Thermo Fisher’s CTS Detachable Dynabeads platform. \nMeanwhile, TMO is expected to have gained from its successful acquisition of Olink Holding AB during the third quarter. \nPer our model, the Life-Science Solutions business is expected to have generated $2.65 billion in revenues for the fourth quarter, calling for a 7.5% improvement year over year.\nThe Specialty Diagnostics segment (Clinical Diagnostics business from the molecular controls that go into testing kits) is expected to have gained positive contributions, led by its transplant diagnostics and immunodiagnostics businesses as well as the healthcare market channel. Additionally, during the fourth quarter, the company received approval from the Food and Drug Administration (“FDA”) for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with VORANIGO tablets.\n\nThermo Fisher Scientific Inc. Price and EPS Surprise\n\nThermo Fisher Scientific Inc. price-eps-surprise | Thermo Fisher Scientific Inc. Quote\n\nIn the previous quarter, TMO partnered with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. The company also launched a pre-transplant risk assessment assay to help assess the risk of early acute rejection in kidney transplant recipients. Moreover, it secured 510(k) FDA clearance for SeCore CDx HLA A Sequencing System for synovial sarcoma. We expect these developments to have had a positive impact on the company’s fourth-quarter top-line performance. \nOur model projects TMO’s Specialty Diagnostics business to report $1.13 billion in revenues, suggesting 2% growth year over year.\nWithin the Laboratory Products and Services segment, revenues are expected to have increased due to the research and safety market channel. During the fourth quarter, the company introduced Thermo Scientific iCAP MX Series ICP-MS, designed for environmental, food, industrial and research labs to analyze routine and challenging trace elements to detect and mitigate harmful substances.\nDuring the third quarter, the company opened its first electron microscopy demo center, NanoPort, in Taiwan. TMO also expanded its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden. This, too, while strengthening the company’s foothold in Taiwan, might have had a favorable impact on TMO’s top line in the to-be-reported quarter. \nOur model expects TMO’s Laboratory Products and Services business’ fourth-quarter revenues to be $5.72 billion, flat year over year. \nWhat Our Quantitative Model Predicts\nPer our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.\nEarnings ESP: Thermo Fisher has an Earnings ESP of +0.65%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.\nZacks Rank: The company currently carries a Zacks Rank #4.\nStocks Worth a Look\nHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.\nArgenx ARGX has an Earnings ESP of +44.82% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. \nThe company is expected to release fourth-quarter 2024 results on March 6. The Zacks Consensus Estimate for EPS implies a surge of 196.4% from the year-ago quarter’s reported figure.\nArcutis Biotherapeutics ARQT has an Earnings ESP of +7.97% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter 2024 results on Feb. 25. ARQT’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 17.46%. \nAxogen AXGN has an Earnings ESP of +36.36% and a Zacks Rank #2 at present. The company is likely to release fourth-quarter 2024 results on March 4. The Zacks Consensus Estimate for EPS implies a surge of 166.7% from the year-ago quarter’s reported figure.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nThermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report\nAxoGen, Inc. (AXGN) : Free Stock Analysis Report\nargenex SE (ARGX) : Free Stock Analysis Report\nArcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505016409"}